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Hepatitis B virus (HBV) is a main cause of chronic and acute hep-
atitis. Healthcare workers (HCWs), including medical students 
and resident doctors, have an occupational risk of HBV infection. 
The study aimed to evaluate the long-term persistence of protec-
tive anti-HBs antibody levels in healthcare students and resident 
doctors at risk for occupational exposure to HBV at 15 years after 
primary vaccination course. Further objective was to evaluate 
the anamnestic response observed in non-seroprotected subjects 
receiving a booster dose. 
Data were collected from the clinical documentation filled in dur-
ing the occupational medical check of medical students and resi-
dent doctors undergoing Occupational Health Surveillance by the 
University of Ferrara.
Of the 621 included individuals, 27.7% had an anti-HBs concen-
tration  <  10  mIU/mL. Subjects vaccinated during infancy had 
more frequently a concentration  <  10 mIU/mL than those vac-
cinated during adolescence (42.7% vs 6.9%; p-value < 0.001). 
Multivariate analysis confirmed the statistical significance of 
the vaccination age. 94 subjects who had an anti-HBs concen-
tration < 10 mIU/mL received a booster dose. The proportion of 
subjects who had an anamnestic response was higher in those 
vaccinated in infancy rather than during adolescence (94.1% vs 
77.8% respectively).
These findings suggest that the anti-HBs concentration decreases 
below 10 mIU/mL more frequently in subjects vaccinated during 
infancy. Immunological memory seems to persist after the decline 
of the anti-HB titer, as observed in response to a booster dose. In 
conclusion, vaccinated subjects at increased risk of HBV infection 
should be monitored and a booster dose administered if anti-HBs 
titer is below 10 mIU/mL.
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Introduction
Hepatitis B virus (HBV) is a serious global health con-
cern and an important occupational risk for healthcare 
workers. HBV is one of the main causes of chronic and 
acute hepatitis, leading to a high risk of death for cirrho-
sis and liver cancer [1, 2].
The World Health Organization (WHO) estimates that, 
globally, 257 million people are infected by HBV or 
positive for hepatitis-B-surface-antigen (HBsAg). In 
2015 HBV caused 887.000 deaths, mostly by complica-
tions [2, 3].
In Europe, a downward trend in the rate of acute cases 
was observed, due to the implementation of immuniza-
tion programmes across several countries in this region. 
However, through the changes in local testing and re-
porting practices, the rate of newly diagnosed chronic 
cases is rising over time [4].
In Italy, according to the National Surveillance System 
(SEIEVA) data, the incidence rate of hepatitis B acute 
cases decreased from 5.4 per 100,000  inhabitants in 
1990 to 2 per 100,000 inhabitants in 2000. This decline 
was even more noticeable among 15-24-year-old people, 
whose incidence rate decreased from 17.4 per 100,000 
to 2 per 100,000 in the same lapse [5-7].
Since 1982, safe and efficacious vaccines are avail-
able [8]. According to the 2017-2019 National Plan of 
Vaccination Prevention (PNPV), healthcare workers 
(HCWs) are at maximum risk to get HBV infection and 
an adequate immunization intervention is essential to 
prevent and control the transmission of HBV in order to 
guarantee the protection in this group of workers. Fur-
thermore, HBV vaccination is strongly advised for stu-
dents involved in healthcare setting. The recommended 
schedule of HBV vaccine consists of three doses admin-
istered at the third, fifth and eleventh months of life. The 
target for HBV vaccine is a coverage rate of at least 95% 
in new-borns [9].
Anti-HBs antibody levels (anti-HBs) ≥ 10 mIU/mL are 
considered protective [10, 11].
Available studies in the literature suggested that im-
munological memory persists even if anti-HBs titer de-
creases under 10 mIU/mL, as confirmed by an amnnes-
tic response after the administration of a booster dose of 
HBV vaccine [3, 12-16].
Monitoring anti-HBsAg antibodies titer in serum and 
the eventual administration of a booster dose could 
be necessary in individuals at risk of exposure, like 
HCWs [10, 17].
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According to the Italian law on Occupational Health 
and Safety (Law Decree 81/2008)  [18] the students, 
the interns and the resident doctors are also included in 
HCWs. When exposed to biological risk, blood tests, in-
cluding HBsAg assessment and anti-HBs titer [19], are 
evaluated. Moreover, the Italian Law Decree 81/2008 
requires the employers to adopt protective measures for 
at risk workers, including providing safe and effective 
vaccines [9, 18, 20].
The recent guidelines developed by Italian region Emil-
ia-Romagna  [20] emphasise the importance of hepati-
tis B vaccine for all HCWs considered at risk even af-
fecting, in some specific cases, fitness to work provided 
by the occupational physicians (e.g., refusing vaccina-
tion, high risk tasks, exposure prone procedures).
The aim of the study was to assess the prevalence and the 
persistence of a positive anti-HBs titer (≥ 10 mIU/mL) in 
medical students and in resident doctors with an occu-
pational risk of HBV infection, approximately 20 years 
after the completion of a full regular vaccination series. 
The immunological memory through the anamnestic re-
sponse to a booster dose in subjects with an anti-HBs 
concentration < 10mIU/mL was also evaluated.
Methods
Study design
A cross-sectional, observational study was conducted. 
Demographic, clinical and laboratory data were collect-
ed through the review of clinical records filled in during 
the Occupational Health Surveillance Program. 
Setting and study population
The study was conducted on medical students and resi-
dent doctors undergoing periodical medical examination 
provided for Occupational Health Surveillance Pro-
gram by the University of Ferrara from January 2011 to 
February 2018. Program is offered free of charge to all 
workers, including students, who have an occupational 
risk for exposure to biological, chemical or physical 
agents [18].
Data were collected from the clinical documentation 
drafted during the Occupational Health Surveillance 
examination and included: age, gender, occupational 
category, vaccination status concerning HBV (date of 
vaccination, age at vaccination, number of doses, type 
of vaccine if available), blood tests (date of blood test, 
anti-HBs concentration, markers of HBV infection). 
The vaccination status was verified through vaccination 
certificates (a document certifying the administration of 
vaccines by the Public Health Department) provided by 
the subjects at the time of the first visit. 
Only students and residents who received three doses of 
recombinant HBV vaccine, at 0 and subsequent 1 and 
6 months from the first dose were included.
All subjects who received incomplete cycles, doses at 
inappropriate intervals, additional doses prior to the as-
sessment of anti-HBs titre or who provided insufficient 
documentation were excluded. All subjects with a posi-
tive HBsAg surface antigen were also excluded.
The enrolled students and residents were classified ac-
cording to the age at vaccination in “vaccinated during 
infancy”, if the vaccination course was administered 
between 0 and 3 years and “vaccinated during adoles-
cence”, if the vaccination course was administered be-
tween 10 and 16 years. Subjects vaccinated at other ages 
were classified as “other age” and were excluded from 
the study.
The received dose was classified as “pediatric” or “adult” 
according to the indications of the Ministry of Health: 
the compulsory vaccination for HBV was introduced in 
Italy in 1991 [21]; from 1991 to 2000, 3 pediatric doses 
were administered to all new-borns starting from the 
third month of life and 3 adult doses to all 12-year-old 
individuals. 
Since 2000, however, the pediatric dose is administered 
up to 16 years of age to subjects who have not been vac-
cinated at birth [19].
According to the WHO recommendations, an anti-HBs 
titer equal to or greater than 10  mIU/mL was consid-
ered as protective [22]. To all subjects with an anti-HBs 
concentration < 10 mIU/mL a booster dose of monova-
lent HBV vaccine was offered, as established by Ital-
ian law [23]. The anti-HBs titer was re-evaluated at least 
four weeks after the administration of the booster dose, 
considering it protective when ≥ 10 mIU/mL.
Statistical analysis
Categorical variables were analysed as frequencies and 
percentages and compared by the Pearson’s Chi-square 
test. The outcome of interest was anti-HBs concentration, 
considered as not protective when < 10 mIU/mL. Levels 
of anti-HBs concentrations have been dichotomized in 
“0” when < 10 mIU/mL and “1” when ≥ 10 mIU/mL. 
The anamnestic response to a booster dose among sub-
jects vaccinated during infancy and among those vac-
cinated in adolescence has been evaluated with the Fish-
er’s exact test. 
To allow the calculation of the geometric mean concen-
trations (GMC), in the case of undetectable concentra-
tions, an arbitrary value of 0.5 mIU/mL was assigned, 
while for concentrations > 1,000 mIU/mL, an arbitrary 
value of 1000 was assigned. 
A multivariate stepwise logistic regression was per-
formed considering as outcome an anti-HBs concentra-
tion < 10 mIU/mL. The logistic regression model was build 
testing the following variables: gender (0 = male, 1 = fe-
male), age at vaccination (0 =  infancy, 1=adolescence), 
vaccine dose (0 = pediatric, 1 = adult), time since vac-
cination (0 = < 15 years, 1 = 15-19 years, 2 = ≥ 20 years). 
Odds Ratios (OR) and 95% confidence intervals (95% CI) 
have been calculated and a p-value < 0.05 has been con-
sidered as statistically significant. Statistical analysis was 
performed with IBM® SPSS® Statistics, version 20.
Ethical approval aspects
The study protocol was approved by the Local Ethics 
Committee. The collection of data was conducted fol-
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lowing the principles of the Declaration of Helsinki, ac-
cording to current national legislation and in compliance 
with the protection of personal data. As no information 
which may identify the subjects was collected, no in-
formed consent was obtained.
Results
The overall population was composed of 678 students 
and resident doctors. 57 subjects were excluded: 23 be-
cause they received a fourth dose before the study, 27 
had incomplete documentations, 6 were not vaccinat-
ed either in infancy or adolescence, 1 resulted HbsAg 
positive. 621 individuals met the inclusion criteria. 172 
(27.7%) had an anti-HBs concentration  <  10  mIU/mL 
and 449 (72.3%) had an anti-HBs titer ≥ 10 mIU/mL.
None of the included subjects was vaccinated with the 
hexavalent vaccines Hexavac or Infarix. 
The univariate analysis (Tab.  I) showed that the per-
centage of subjects vaccinated during infancy with a 
titer < 10 mIU/mL was significantly higher than in sub-
jects immunized during adolescence (154/361 or 42.7% 
vs 18/260 or 6.9%; OR = 0.1; 95% CI = 0.1-0.2; p-val-
ue  <  0.001) (Fig.  1). The percentage of subjects who 
received a complete vaccination course with pediatric 
doses and had an anti-HBs concentration < 10 mIU/mL 
was significantly higher than that of the subjects vacci-
nated with adult doses (162/450 or 36.0% vs 10/171 or 
5.8%; OR 0.1; 95% CI = 0.1-0.2; p-value < 0.001).
The average period between the completion of the 
first immunization cycle and the evaluation of anti-
HBs was 20.4 years (SD  =  2.2) for the subjects with 
titer  <  10  mIU/mL and 18.3 years (SD  =  3.3) for the 
subjects with concentration ≥ 10 mIU/mL. The mean age 
of immune subjects was 25.3 years (SD = 3.4) while in 
seronegative individuals was 22.6 years (SD = 2.4).
The logistic regression model (Tab.  II) confirmed the 
statistical significance of age at vaccination (infancy 
versus adolescence, OR = 0.2; 95% CI = 0.1-0.8; p-val-
ue = 0.02) as independent predictive variable associated 
with an outcome of anti-HBs concentration < 10 mIU/
mL.
As regards to age at first immunization, the 27.4% of 
subjects vaccinated during infancy and 2.3% of those 
immunized in adolescence showed undetectable anti-
HBs titers (Tab. III).
The GMC of anti-HBs before booster dose was high-
er among subjects vaccinated during adolescence 
(158.2  mIU/mL with 95% CI  =  128.2-194.8) than in 
those immunized during infancy (11.1  mIU/mL with 
95% CI = 8.7-14.0).
Although a booster dose was offered to all seronegative 
subjects, only 94 subjects had an available blood test at 
the moment of the study as showed in Table IV: 85 vac-
cinated during infancy (55.2%) and 9 vaccinated during 
adolescence. 
The rate of subjects showing an anamnestic response af-
ter the booster dose was higher in individuals vaccinated 
during infancy (80/85 or 94.1% vs 7/9 or 77.8%). This 
difference was however not statistically significant (p-
value = 0.13). 
After receiving the booster dose, 91.9% (57 out of 62) 
of subjects with a previously undetectable anti-HBs con-
centration and 93.8% (30 out of 32) of those with a pre-
viously detectable but < 10 mIU/mL titer, achieved an 
anamnestic response (p-value = n.s.). None of the sub-
jects resulted non-responder since they all reached an 
anti-HBs titer ≥ 10 mIU/mL within the secondary vac-
cination course (at 4th, 5th or 6th dose).
The GMC of anti-HBs after booster dose resulted 
241.2  mIU/mL (95% CI  =  167.7-348.7) in subjects 
immunized during the infancy and 72.7  mIU/mL 
(95%  CI  =  21.9-278.6) in subjects vaccinated during 
adolescence.
Discussion
Most medical students and resident doctors included in 
the study (72.3%) showed, at the occupational health 
surveillance check, a protective anti-HBs titer even 15-
20 years after the first cycle of vaccination. This find-
ing confirms the current knowledge concerning the 
long-term persistence of seroprotection levels in appro-
priately vaccinated subjects, as described in the litera-
ture [24, 25].
Tab. I. Demographic and epidemiological characteristics.
Anti-HBs < 10 mIU/mL
(N = 172)
Anti-HBs ≥ 10 mIU/mL
(N = 449)
P-value
Gender
• Male (n, %)
• Female (n, %)
74, 43.0%
98, 57.0%
170, 37.9%
279, 62.1%
n.s.
n.s.
Age at HBV vaccination
• Infancy (0-3 years), %
• Adolescence (10-16 years), %
89.5
10.5
46.1
53.9
< 0.001
Vaccine dose
• Pediatric, %
• Adult, %
94.2
5.8
64.1
35.9
< 0.001
Time since vaccination
mean ± SD (years)
20.4 ± 2.2 18.3 ± 3.2 < 0.001
Age at testing
mean ± SD (years)
22.6 ± 2.4 25.3 ± 3.4 < 0.001
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The study showed that, 15-20  years after the primary 
HBV vaccination course, there is a significant differ-
ence between the rate of subjects vaccinated during 
infancy who did not maintain an anti-HBs concentra-
tion ≥ 10 mIU/mL and that of those immunized during 
adolescence (42.7% and 93.1% respectively). Similarly 
to other studies [3, 26, 27], the 27.4% of subjects vac-
cinated during infancy also had an undetectable anti-
HBs concentration and a GMC before booster dose of 
11.1 mIU/mL. 
Factors such as age at vaccination, vaccine dosage [1, 3] 
and host genetic factors [28] play a fundamental role in 
maintaining the anti-HBs concentration. Furthermore, 
the higher the antibody response after the primary vac-
cination cycle, the longer the persistence of an anti-HBs 
concentration above the 10 mIU/mL threshold [1]. The 
results arisen in this study reinforce the importance of 
age at vaccination, as highlighted by the statistical sig-
nificance in the multivariate analysis (OR 0.2; 95% 
CI = 0.1-0.8).
Fig. 1. Seroprevalence against HBV according to the age at primary vaccination course.
Tab. II. Results of a logistic regression model estimating predictors of an anti-HBs titer < 10 mIU/mL in HBV vaccinated subjects.
Outcome: anti-HBs titer < 10 mIU/mL
N = 621
OR 95% CI P-value
Gender
• Male
• Female
1.0
1a
0.6-1.4 0.81
Age at HBV vaccination
• Infancy (0-3 years)
• Adolescence (10-16 years)
0.2
1a
0.1-0.8 0.02
Vaccine dose
• Pediatric
• Adult
0.7
1a
0.2-1.9 0.48
Time since vaccination
• < 15 years
• 15-19 years
• ≥ 20 years
1a
1.9
0.9
0.7-5.5
0.2-3.4
0.12
0.84
CI:  Confidence Interval; a: reference category.
Tab. III. Anti-HBs concentrations (mIU/mL) and Geometric Mean Concentration (GMC) before booster dose.
Anti-HBs concentrations Infancy 
(0-3 years)
N = 361 (%)
Adolescence 
(10-16 years)
N = 260 (%)
Undetectable 99 (27.4) 6 (2.3)
• 1 to < 10 mIU/mL
• 10 to < 100 mIU/mL
• 100 to < 1,000 mIU/mL
• ≥ 1,000 mIU/mL
55 (15.2)
150 (41.6)
55 (15.2)
7 (1.9)
12 (4.6)
82 (31.5)
92 (35.4)
68 (26.2)
GMC before booster dose
mIU/mL (95% CI) 11.1 (8.7-14.0) 158.2 (128.2-194.8)
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The immune system in childhood is characterized by an 
impaired T-cell function, by lower interactions between 
B and T cells, by a reduced assortment of immunoglobu-
lins and by a low affinity antibody response [29].
The anamnestic response to a booster dose in individuals 
with an anti-HBs concentration < 10 mIU/mL was de-
tected, particularly in subjects vaccinated during infan-
cy: 80 subjects out of 85 (94.1%) recovered a protective 
titer with a GMC of 241.2 mIU/mL. The response was 
less pronounced in subjects with anti-HBs concentra-
tions < 10 mIU/mL and vaccinated during adolescence, 
although no statistically conclusive hypotheses can be 
conceived due to the small number of available blood 
test. Among the medical students and resident doctors 
who received a booster dose, no significant difference 
was found in the anamnestic response between those 
who had an undetectable anti-HBs titer and those who 
had a detectable but not protective anti-HBs titer. These 
results are consistent with previous studies and seem to 
confirm the hypothesis that the immunological memory 
is preserved even after the loss of anti-HBs antibody ti-
ter  [10, 30]. Such evidence acquires significance in an 
occupationally exposed population at greater risk for 
HBV. As recently pointed out by the review of Zhao 
and Zhou [31], whether booster or revaccination after a 
period of time following the primary vaccination is re-
quired remains a debated issue. Nonetheless a booster 
response could be observed in most of subjects vacci-
nated 30 years ago, as confirmed by breakthrough HBV 
infection with severe consequences in successfully vac-
cinated individuals is extremely rare. 
The waning immunity against HBV should be particu-
larly monitored in high-risk groups. Occupational Phy-
sicians should consider with particular attention the 
evaluation of the persistence of anti-HBV specific an-
tibodies in medical students (in most cases vaccinated 
at birth age) and HCWs specifically at the time of the 
first employment in order to identify subjects with non-
protective anti-HBs titer  [32, 33]. Occupational Physi-
cians’ contribution to reduce vaccine delays or refusals 
and vaccine hesitancy that are also affecting HCWs is 
crucial [34]. A recent study of Riccò and colleagues [35] 
draw attention to the knowledge, attitudes, beliefs and 
practices of Occupational Physicians towards vaccina-
tion in HCWs showing that severity perception of the 
disease and misconceptions about vaccines still influ-
ence the immunization coverage. As only evidence-
based recommendations should guide occupational phy-
sicians’ behaviour towards vaccination, specific training 
programs and formations courses are strongly needed.
The main limitations of this study are represented by 
the intrinsic characteristics of the study design and the 
incomplete data of a part, albeit limited, of the clinical 
documentation.
In particular, at the moment of the study, only a part of 
blood tests was available.
Some anamnestic data could play an important role on 
the long-term immunogenicity of the vaccine [36]. The 
reduced number of subjects with anti-HBs concentra-
tion < 10mIU/mL vaccinated during adolescence did not 
allow to detect significant differences in the booster dose 
response in this subgroup. Furthermore, not all subjects 
eligible for the administration of a booster dose accepted 
the recommendation. 
Conclusions
The results of the study, accordingly to literature, sug-
gest that anti-HBs titers have a tendency to decrease be-
low the threshold of 10 mIU/mL in vaccinated subjects. 
Immunological memory, however, seems to persist in al-
most all individuals even after the reduction of the anti-
HBs concentrations to undetectable levels, as observed 
in response to a booster dose. In conclusion, assessing 
seroprotection within public health programmes is not 
considered a cost-effective practice. In order to fill this 
gap, the Advisory Committee on Immunization Prac-
tices (ACIP) recommends testing health care personnel 
for anti-HBs antibodies levels before their occupational 
exposure. A positive result of the test (≥  10mUI/mL) 
provides no further intervention. On the other hand, one 
or more additional doses of HBV vaccine and retesting 
is recommended in non-seroprotected subjects [37]. Oc-
cupational Health Surveillance Programs represent the 
best opportunity to perform these activities and recom-
mendations, allowing also both to verify the anamnestic 
response to booster vaccination and the persistence of 
immunological memory. All these actions are supported 
from our results and contribute to the control of HBV 
transmission among HCWs and undergraduate health-
care students.
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Tab. IV. Anti-HBs concentrations and Geometric Mean Concentration (GMC) after booster dose.
Infancy (0-3 years)
after booster dose
N = 85 (%)
Adolescence (10-16 years)
after booster dose
N = 9 (%)
P-value
Anti-HBs concentration before 
booster dose:
• anti-HBs < 10 mIU/mL
• anti-HBs ≥ 10 mIU/mL
5 (5.9)
80 (94.1)
2 (22.2)
7 (77.8) 0.13
GMC after booster dose 
mIU/mL (95% IC) 241.2 (167.7-348.7) 72.7 (21.9-278.6)
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